Browse hierarchy: [Neurology (NE)](/submissions/NE) → [Subpart F — Neurological Therapeutic Devices](/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices) → [21 CFR 882.5894](/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/882.5894) → OSG — Piezo-Electric Stimulator For Relief Of Mosquito Bite Itch

# OSG · Piezo-Electric Stimulator For Relief Of Mosquito Bite Itch

_Neurology · 21 CFR 882.5894 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/OSG

## Overview

- **Product Code:** OSG
- **Device Name:** Piezo-Electric Stimulator For Relief Of Mosquito Bite Itch
- **Regulation:** [21 CFR 882.5894](/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/882.5894)
- **Device Class:** 2
- **Review Panel:** [Neurology](/submissions/NE)

## Identification

A limited output transcutaneous piezoelectric stimulator for skin reactions associated with insect bites is a device intended to alleviate skin reactions associated with insect bites via cutaneous, piezoelectric stimulation at the local site of the bite.

## Classification Rationale

Class II (special controls). The special controls for this device are:

## Special Controls

In combination with the general controls of the FD&C Act, the Limited output transcutaneous piezoelectric stimulator for skin reactions associated with insect bites is subject to the following special controls:

- 1. Appropriate testing to characterize the electrical output specifications of the device (i.e., total charge delivered, maximum instantaneous output current, maximum instantaneous output

voltage, pulse duration, charge density) must be conducted.

- 2. Mechanical bench testing must demonstrate that the device will withstand the labeled number duration of uses.
- 3. All elements of the device that may contact the patient must be assessed to be biocompatible.
- 4. Labeling must include:
	- a. Validated instructions which addresses the following:
		- i. Identification of areas of the body which are appropriate and not appropriate for contact with the device;
		- ii. Whether use of the device in conjunction with flammable materials (e.g., insect repellent) is appropriate;
		- iii. Use of the device on or near implanted devices;
		- iv. How to identify the correct type of skin condition
	- b. Technical parameters of the device [maximum output voltage (instantaneous), maximum output current (instantaneous), and pulse duration].
	- Language to direct end-users to contact the device manufacturer and MedWatch if C. they experience any adverse events with this device.
	- d. The anticipated number of device uses prior to failure.

In combination with the general controls of the FD&C Act, the Limited output transcutaneous piezoelectric stimulator for skin reactions associated with insect bites.is subject to the following special controls:

- 1. Appropriate testing to characterize the electrical output specifications of the device (i.e., total charge delivered, maximum instantaneous output current, maximum instantaneous output voltage, pulse duration, charge density) must be conducted.
- 2. Mechanical bench testing must demonstrate that the device will withstand the labeled number duration of uses.
- 3. All elements of the device that may contact the patient must be assessed to be biocompatible.
- 4. Labeling must include:
	- a. Validated instructions which addresses the following:
		- i. Identification of areas of the body which are appropriate and not appropriate for contact with the device;
		- ii. Whether use of the device in conjunction with flammable materials (e.g., insect repellent) is appropriate;
		- iii. Use of the device on or near implanted devices;
		- iv. How to identify the correct type of skin condition
	- b. Technical parameters of the device [maximum output voltage (instantaneous), maximum output current (instantaneous), and pulse duration].
	- c. Language to direct end-users to contact the device manufacturer and MedWatch if they experience any adverse events with this device.
	- d. The anticipated number of device uses prior to failure.

*Classification.* Class II (special controls). The special controls for this device are:(1) Appropriate testing to characterize the electrical output specifications of the device (
*i.e.,* total charge delivered, maximum instantaneous output current, maximum instantaneous output voltage, pulse duration, charge density) must be conducted.(2) Mechanical bench testing must demonstrate that the device will withstand the labeled number duration of uses.
(3) All elements of the device that may contact the patient must be assessed to be biocompatible.
(4) Labeling must include:
(i) Validated instructions which addresses the following:
(A) Identification of areas of the body which are appropriate and not appropriate for contact with the device.
(B) Whether use of the device in conjunction with flammable materials (
*e.g.,* insect repellent) is appropriate.(C) Use of the device on or near implanted devices.
(D) How to identify the correct type of skin condition.
(ii) Technical parameters of the device (maximum output voltage (instantaneous), maximum output current (instantaneous), and pulse duration).
(iii) Language to direct end users to contact the device manufacturer and MedWatch if they experience any adverse events with this device.
(iv) The anticipated number of device uses prior to failure.

## Recent Cleared Devices (2 of 2)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [DEN130019](https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/OSG/DEN130019.md) | ZANZA-CLICK | Tecnimed S.R.L. | Nov 7, 2014 | DENG |
| [DEN100024](https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/OSG/DEN100024.md) | ZAP-IT! | Ecobrands , Ltd. | Nov 7, 2014 | DENG |

## Top Applicants

- Ecobrands , Ltd. — 1 clearance
- Tecnimed S.R.L. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/OSG](https://fda.innolitics.com/submissions/NE/subpart-f%E2%80%94neurological-therapeutic-devices/OSG)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com